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Abstract 
Background: Leflunomide is a low‑molecular‑weight compound that is widely used in the treatment of rheuma‑
toid arthritis. Although leflunomide is thought to act through the inhibition of the de novo pyrimidine synthesis, the 
molecular mechanism of the drug remains largely unknown. We investigated the antiarthritis effects and mechanisms 
of action of the active metabolite of leflunomide, A77 1726, in interleukin‑1 receptor antagonist‑knockout (IL‑1Ra‑KO) 
mice.
Methods: 14‑ to 15‑week‑old male IL‑1Ra‑KO mice were treated with 10 or 30 mg/kg A77 1726 via intraperitoneal 
injection three times per week for 6 weeks. The effects of A77 1726 on arthritis severities were assessed by clinical 
scoring and histological analysis. The serum concentrations of IL‑1β, tumor necrosis factor‑α (TNF‑α), and malondi‑
aldehyde were measured by enzyme‑linked immunosorbent assay. Histologic analysis of the joints was performed 
using Safranin O, and immunohistochemical staining. The frequencies of interleukin‑17‑producing CD4+ T (Th17) cells 
were analyzed by flow cytometry. Heme oxygenase‑1 (HO‑1) expression in splenic CD4+ T cells isolated from A77 
1726‑treated arthritis mice were assessed by western blotting.
Results: A77 1726 treatment induced heme oxygenase‑1 (HO‑1) in Jurkat cells and primary mouse T cells. Interest‑
ingly, A77 1726 inhibited Th17 cell differentiation. In vivo, A77 1726 reduced the clinical arthritis severity of histological 
inflammation and cartilage destruction. The joints isolated from A77 1726‑treated mice showed decreased expression 
of inducible nitric oxide synthase, nitrotyrosine, TNF‑α, and IL‑1β. The serum levels of TNF‑α, IL‑1β, and malondialde‑
hyde were also decreased in A77 1726‑treated mice. Whereas the number of Th17 cells in spleens was decreased in 
A77 1726‑treated arthritis mice, a significant increase in the number of Treg cells in spleens was observed. Interest‑
ingly, HO‑1 expression was significantly higher in splenic CD4+ T cells isolated from A77 1726‑treated mice compared 
with those from vehicle‑treated mice, whereas HO‑1 expression of splenic non‑CD4+ T cells did not differ between 
groups.
Conclusion: The inhibitory effects of A77 1726 on joint inflammation and oxidative stress in autoimmune arthritis 
may be associated with HO‑1 induction in CD4+ T cells.
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Background
Rheumatoid arthritis (RA) is a debilitating, chronic auto-
immune polyarthritis, characterized by synovial hyper-
trophy and inflammatory cell infiltration in the affected 
joints. Although the pathogenesis of RA remains elusive, 
it is known to involve many cell types, including CD4+ 
T cells and B cells, in the inflamed hypertrophic syn-
ovium, called “pannus”. These cells play pathological roles 
in the development of RA by producing cytokines that 
perpetuate rheumatoid inflammation [1]. Therefore, the 
major targets of RA treatment are the proinflammatory 
immune cells, especially CD4+ T cells, which are a piv-
otal player in the development and progression of RA, 
and their production of inflammatory cytokines, such as 
tumor necrosis factor-α (TNF- α), interleukin 1β (IL-1β), 
and IL-17. Among the T cell subsets, a distinct lineage of 
IL-17-producing effector T helper cells, called Th17 cells, 
have been identified to be involved in the pathogenesis 
of RA [2]. On the opposite side of Th17 cells, there are 
Foxp3-expressing regulatory T (Treg) cells that have a 
pivotal role in suppressing immune responses [3]. Accu-
mulating scientific evidences have revealed that many 
autoimmune diseases including RA result from an imbal-
ance between Treg cells and Th17 cells [4–6]. The poten-
tial role of Treg cells as a treatment target for RA has 
attracted increasing interest [7]. Furthermore, the plas-
ticity between Treg and Th17 cells indicates that Th17/
Treg imbalance plays a critical role during the develop-
ment and progression of RA [8, 9]. Thus, the reciprocal 
regulation of Th17/Treg subsets can be a novel therapeu-
tic strategy for RA.
Although the pathogenesis of RA is not understood 
clearly, altered oxidative stress is considered to play a 
critical role during the development and perpetuation 
of the disease [10, 11]. Over the course of evolution, 
defensive mechanisms against oxidative stress have been 
developed. One major mechanism in the cellular defense 
against oxidative stress is activation of the nuclear-related 
factor 2 (Nrf2), a key transcription factor that contrib-
utes to the maintenance of cellular redox homeostasis 
[12]. One of the major stress-responsive players regulated 
by Nrf2 is the antioxidant enzyme heme oxygenase-1 
(HO-1). Nrf2 signaling has received recent attention as 
a participant in the pathogenesis of RA. A deficiency in 
the Nrf2 pathway in an animal model of RA was associ-
ated with aggravated arthritis severity and osteoporosis, 
and may indicate the potential protective role of func-
tional Nrf2–HO-1 signaling in RA [13]. It has also been 
reported that impairment in the antioxidant systems 
leads to increased oxidative stress in RA [14].
Leflunomide is an oral drug that inhibits de novo 
pyrimidine synthesis by inhibiting dihydroorotate dehy-
drogenase and was originally developed for the synthesis 
of agricultural pesticides [15]. Leflunomide exerts immu-
noregulatory properties and is useful in RA treatment, 
and has been introduced as a synthetic disease-modifying 
antirheumatic drug (DMARD) [16]. The immunomod-
ulatory action of leflunomide is mediated primarily 
through the effect of its water-soluble metabolite, termed 
A77 1726. Despite the clinical usefulness of the drug, the 
underlying mechanisms of the drug remain elusive. The 
immunosuppressive activity has been shown to be inde-
pendent of pyrimidine synthesis inhibition [17, 18].
Although many DMARDs are believed to affect oxi-
dative stress in RA, there is insufficient research data to 
confirm this circumstantial assumption. Thus, in the pre-
sent study, we explored the in  vivo effects of the active 
metabolite of leflunomide, A77 1726, in an animal model 
of RA. We used IL-1 receptor antagonist-knockout 
(IL-1Ra-KO) mice to investigate the underlying mecha-




IL-1Ra-KO mice with the BALB/c background were 
kindly provided by Professor Yoichiro Iwakura (Univer-
sity of Tokyo, Japan) and were maintained under spe-
cific pathogen-free conditions at the Institute of Medical 
Science, Catholic University of Korea, and fed standard 
mouse chow (Ralston Purina, St Louis, MO, USA) and 
water ad  libitum. All experimental procedures were 
examined and approved by the Animal Research Ethics 
Committee of the Catholic University of Korea, which 
conformed to all National Institutes of Health of the USA 
guidelines. Mice were euthanized at the end of a study for 
the purpose of sample collection and histologic exami-
nation by CO2 chamber. The experimental protocol was 
approved, and all animals were treated and sacrificed in 
accordance with the guidelines of the Catholic university 
of Korea on Use and Care of Animals.
Treatment with A77 1726
To assess the therapeutic effect of A77 1726 on symptom 
severity in the IL-1Ra-KO mouse model, 14–15-week-old 
male IL-1Ra-KO mice were treated with 10 or 30 mg/kg 
A77 1726 (Santa Cruz Biotechnology, Santa Cruz, CA, 
USA) dissolved in dimethyl sulfoxide (DMSO) or with 
vehicle alone, via intraperitoneal injection three times per 
week for 6 weeks. The clinical signs of arthritis in IL-1Ra-
KO mice were monitored two times a week by inspection 
and were quantified using an arthritis score, as reported 
previously [19]. The final arthritis score was calculated as 
the sum of scores from all four legs, which were assessed 
by three independent observers with no knowledge of the 
experimental groups.
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Tissue scoring
The H&E stained sections were scored for inflamma-
tion and bone erosion. Inflammation was scored accord-
ing to the following criteria [20] : 0 = no inflammation, 
1  =  slight thickening of the lining layer or some infil-
trating cells in the underlying layer, 2 =  slight thicken-
ing of the lining layer plus some infiltrating cells in the 
underlying layer, 3  =  thickening of the lining layer, an 
influx of cells in the underlying layer and the presence 
of cells in the synovial space, and 4 =  synovium highly 
infiltrated with many inflammatory cells. Cartilage dam-
age was determined using safranin-O staining, and the 
extent of cartilage damage was scored according to the 
following criteria: 0 = no destruction, 1 = minimal ero-
sion limited to single spots, 2 = slight to moderate ero-
sion in a limited area, 3 = more extensive erosion, and 
4  =  general destruction [20]. The extent of bone ero-
sion was expressed using a scoring system from 0 to 5 
(0 = no erosion, 1 = small areas of resorption not readily 
apparent at low magnification, in the trabecular or cor-
tical bone, 2 = more numerous areas of resorption, not 
readily apparent at low magnification, in the trabecular 
or cortical bone, 3 =  obvious resorption of the trabec-
ular and cortical bone, without full-thickness defects 
in the cortex, loss of some trabeculae, lesions apparent 
at low magnification, 4  =  full-thickness defects in the 
cortical bone and marked trabecular bone loss, without 
distortion of the profile of the remaining cortical sur-
face, and 5 =  full-thickness defects in the cortical bone 
and marked trabecular bone loss, with distortion of the 
profile of the remaining cortical surface), as previously 
described [21].
T cell isolation from each group of mice
On day 42 after the first A77 1726 injection, the spleen 
was removed from each mouse in the different groups. 
The spleen tissue was minced. Splenic red blood cells 
were removed with an ACK lysis buffer (2.06% Tris [pH 
7.65], 0.83% NH4Cl). The cell suspension was passed 
through a 40  μm strainer (BD Falcon, Bedford, MA, 
USA) and resuspended in 5% fetal bovine serum (Gibco, 
Grand Island, NY, USA) containing RPMI 1640 (Gibco) 
medium. Spleen cells were washed with 0.5% bovine 
serum albumin (BSA, Sigma, St. Louis, MO, USA) and 
5  mM ethylenediaminetetraacetic acid (EDTA, Sigma) 
containing phosphate-buffered saline (PBS) buffer (pH 
7.2). After centrifugation at 1300  rpm and 4  °C, the 
cells were incubated with CD4-coated magnetic beads 
(Miltenyi Biotec, Bergisch Gladbach, Germany) and iso-
lated on MACS separation columns (Miltenyi Biotec). 
Positively selected CD4+ T cells were collected for west-
ern blotting and real-time polymerase chain reaction 
(PCR).
Histology and immunohistochemical analysis
Mouse joint tissue was fixed in 4% paraformaldehyde, 
decalcified in EDTA bone decalcifier, and embedded 
in paraffin. Tissue sections (7  μm) were prepared and 
stained with hematoxylin and eosin (H&E), and Safranin 
O to enable evaluation of proteoglycan content. Con-
focal microscopy was used to detect immunostaining 
for IL-17-producing CD4+ T (Th17) and CD4+ CD25+ 
Foxp3+ regulatory T (Treg) cells, as previously described 
[22]. Slides for immunohistochemistry were deparaffi-
nized and rehydrated using a graded ethanol series. The 
sections were depleted of endogenous peroxidase activ-
ity by adding methanolic H2O2 and then blocked with 
normal goat serum for 30  min. The samples were incu-
bated overnight at 4 °C with antibodies to IL-1β at a dilu-
tion of 1:50 (Santa Cruz Biotechnology), inducible nitric 
oxide synthase (iNOS) at 1:100 (Abcam), nitrotyrosine at 
1:100 (Santa Cruz Biotechnology), and TNF-α. The sam-
ples were then incubated with the relevant secondary 
antibody, biotinylated anti-mouse IgG or rabbit IgG, for 
20 min, conjugated to a streptavidin peroxidase complex 
(Vector Laboratories) for 1 h, and finally with 3,3′-diam-
inobenzidine (Dako). To detect HO-1 expressing spleno-
cytes, immunohistochemistry was performed using the 
Vectastain ABC kit. Tissues were first incubated with 
primary anti-HO-1 antibodies overnight at 4  °C. The pri-
mary antibody was detected with a biotinylated secondary 
antibody followed by incubation with a streptavidin-per-
oxidase complex for 1   h. DAB chromogen was added to 
obtain colored product. The sections were counterstained 
with Mayer’s hematoxylin and photographed using an 
Olympus photomicroscope (Olympus, Tokyo, Japan).
Confocal and immunofluorescence microscopy
Tissues were obtained 43  days after first injection of 
A77 1726, snap-frozen in liquid nitrogen, and stored at 
−80 °C. Tissue cryosections (7 μm thick) were fixed and 
permed in acetone and stained for Tregs using allophy-
cocyanin (APC)-labeled anti-CD25 (Biolegend), phy-
coerythrin (PE)-labeled anti-FoxP3 (eBioscience), and 
Alexa488-conjugated anti-CD4 (Biolegend). To stain Th17 
cells, PE-labeled anti-IL-17 (eBioscience), Alexa Fluor ® 
488-conjugated anti-CD4 (BioLegend), PE-labeled anti-
STAT3 phosphorylation at tyrosine 705 (pSTAT3Tyr705) 
or at serine 727 (pSTAT3Ser727) (both from BD Bio-
sciences) were used. To detect p-STAT5, the sections were 
incubated overnight at 4  °C with the primary antibody 
(Cell Signaling), and were followed by staining with PE-
conjugated rabbit secondary antibody (Southern Biotech). 
After an overnight incubation at 4 °C, the stained sections 
were visualized by confocal microscopy (LSM 510 Meta; 
Zeiss, Göttingen, Germany). Jurkat cells were cultured 
at a density of 5 ×  105/ml in six-well plates, exposed to 
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A77 1726 or vehicle (DMSO) for 24 or 48  h, harvested, 
and fixed at room temperature with 2% paraformaldehyde 
in PBS. The cells were washed three times with PBS for 
5 min and permeabilized with 0.1% Triton X-100 in PBS. 
Nonspecific antibody binding was blocked by incuba-
tion with 5% normal goat serum in PBS for 1 h at room 
temperature. The cells were then incubated overnight at 
4  °C with a rabbit polyclonal anti-Nrf2 antibody (1:100 
dilution; Abcam) or anti-HO-1 antibody (1:250 dilu-
tion, Novus Biologicals, Littleton, CO, USA) and washed 
three times with PBS. Next, a secondary antibody (FITC-
labeled goat anti-rabbit IgG, 1:200 dilution; Santa Cruz 
Biotechnology) was applied, and the cells were incubated 
in a dark chamber for 45  min, and then counterstained 
with DAPI for 5 min. The cells were washed with PBS, and 
antifade mounting medium (Gel-Mount; BioMeda) and 
a coverslip were applied. Staining was evaluated using a 
fluorescence microscope (BX50; Olympus).
Murine T cell isolation and differentiation
The C57BL/6 (B6) mouse spleens were collected for cell 
preparation and washed twice with PBS. The spleens 
were minced, and the red blood cells were lysed with 
0.83% ammonium chloride. The cells were filtered 
through a cell strainer and centrifuged at 1300 revolu-
tions per minute for 5  min at 4  °C. To purify splenic 
CD4+ T cells, the splenocytes were incubated with CD4-
coated magnetic beads and isolated using MACS separa-
tion columns (Miltenyi Biotec). Th17 cells were polarized 
with plate-bound anti-CD3 (0.5  μg/ml), soluble anti-
CD28 (1 μg/ml), anti–interferon-γ (anti-IFNγ; 2 μg/ml), 
anti-IL-4 (2  μg/ml), IL-6 (20  ng/ml), and transforming 
growth factor β (TGF β; 2 ng/ml) for 72 h.
Intracellular staining and flow cytometry
The following antibodies were used for intracellular stain-
ing of cells: PerCP-Cy5.5-conjugated anti-CD4, APC-
conjugated anti-CD25, FITC-conjugated anti-IL-17A, 
and PE-conjugated anti-FoxP3 (all from eBioscience).
Enzyme‑linked immunosorbent assay (ELISA)
Sandwich ELISA kits were used to measure the 
amounts of IL-1β (R&D Systems, Minneapolis, MN, 
USA), TNF-α (R&D Systems), and malondialdehyde 
(MDA) (MyBioSource, Inc., San Diego, CA, USA) in 
sera obtained from the mice.
HO‑1 Real‑time PCR and Western blot analysis
RNA was collected with RNeasy plus Mini Kit (QIA-
GEN, Valencia, CA, USA) from the cells purified CD4± 
splencyte. Treatment with deoxyribonuclease 1 (QIA-
GEN) eliminated genomic DNA, and 1ug purified RNA 
was reverse transcribed into first-strand complementary 
DNA using an Quantitect reverse transcription kit (QIA-
GEN, Valencia, CA, USA), which includes a genomic 
DNA elimination step. Real-time polymerase chain reac-
tion (RT-PCR) amplification and relative quantification 
of heme oxygenase 1 (Hmox1) was performed using 
TaqMan gene expression assays (Table  1) (Applied Bio-
systems, Foster City, CA, USA) on a lightcycler 480 PCR 
system (Roche, Mannheim, Germany). All assays used 
similar amplification efficiency, and a delta cycle thresh-
old experimental design was used for relative quantifi-
cation. The reactions were performed in triplicates in a 
20 UL volume using TaqMan probe Master Mix (Roche), 
and 20 ng complementary DNA was used in each reac-
tion. Glyceraldehyde 3-phosphate dehydrogenase served 
as an endogenous control. Results were analyzed using 
lightcycler 480 instrument software 1.2 (Roche, Man-
nheim, Germany). Protein concentration was determined 
using the Bradford method (Bio-Rad, Hercules CA, 
USA). Protein samples were separated using 10% sodium 
dodecyl sulfate–polyacrylamide gel electrophoresis and 
transferred to a nitrocellulose membrane (Amersham 
Pharmacia Biotech, NJ, USA). The membrane was prein-
cubated with 5% skim milk in Tris-buffered saline (TBS) 
for 2 h at room temperature. Primary antibodies against 
HO-1 (Novus Biologicals), and β-actin (Cell Signaling 
Technology, Beverly, MA, USA) were diluted 1:1000 in 
5% BSA-TBS with 0.1% Tween 20 (TBST) added, and the 
samples were incubated overnight at 4  °C. The samples 
were washed four times with TBST, horseradish perox-
idase-conjugated secondary antibodies were added, and 
the samples were incubated for 1 h at room temperature. 
The samples were washed in TBST, and the hybridized 
bands were detected with an ECL detection kit (Pierce) 
and analyzed using a ChemiDoc XRS system with image 
Lab software (Bio-Rad Laboratories).
Statistical analysis
Statistical analysis was performed using IBM SPSS Sta-
tistics 20 for Windows (IBM Corp., Armonk, NY, USA). 
One-way analysis of variance followed by the Bonferroni 
Table 1 Gene expression assays used for real-time polymerase chain reaction for mouse splenocyte
Gene Abbreviation Reference sequence Assay number
Heme oxygenase 1 Hmox1 NM_010442.2 Mm00516005_m1
Glyceraldehyde‑3‑phosphate dehydrogenase Gapdh NM_001289726.1 Mm99999915_g1
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post hoc test was used to compare differences between 
three or more groups. Comparison of numerical data 
between two groups was performed using the Mann–
Whitney U test, and P values <0.05 were considered sig-
nificant. The data are presented as the mean ± standard 
deviation (SD).
Results
A77 1726 induces Nrf2‑HO‑1 axis and inhibited Th17 
differentiation in a dose‑dependent manner in vitro
First, we examined whether A77 1726 exerts a positive 
impact on the Nrf2-mediated HO-1 induction in Jurkat 
T cells. Nrf2 activity in Jurkat cells treated with A77 1726 
was increased in a dose-dependent manner compared 
with vehicle (DMSO)-treated cells (Fig. 1a). As expected, 
HO-1 activity in Jurkat cells was also increased by A77 
1726 treatment in a dose-dependent manner (Fig.  1b). 
Next, to confirm the induction property of A77 1726 
on the Nrf2-HO-1 axis, A77 1726 was treated in IL-
6-stimulated mouse primary T cells isolated from normal 
C57BL/6 mice. The results also showed the same results 
(Fig. 1c, d). To investigate the effects of A77 1726 under 
Th17 cell-polarizing conditions, isolated murine CD4+ 
T cells were cultured in the presence of anti-CD3, anti-
CD28, TGF-β, IFN-γ, IL-4 and IL-6 with or without A77 
1726 for 72  h. The flow cytometry results showed that 
Th17 cell differentiation is suppressed by A77 1726 in a 
dose-dependent manner (Fig. 1e).
A77 1726 inhibits the arthritis severity in a mouse model 
of RA
Based on the in  vitro results above, we investigated 
whether treatment with A77 1726 would suppress 
the development and severity of arthritis in  vivo. A77 
1726 (10 or 30 mg/kg) was administered for 6 weeks to 
14–15-week-old male spontaneous arthritic IL-1Ra-
KO mice. At the beginning of A77 1726 treatment, the 
mice of all the groups showed the signs of joints inflam-
mation. Mean arthritis scores at that time were 2.3, 3.4 
and 4.1 in vehicle-, 10  mg/kg-, and 30  mg/kg-treated 
groups, respectively. At the beginning of treatment, 
there was no significant difference in arthritis severi-
ties between the three groups. Treatment of mice with 
A77 1726 at 30 mg/kg, but not at 10 mg/kg, significantly 
ameliorated the arthritis severity compared with that in 
the wild-type and vehicle (DMSO)-treated IL-1Ra-KO 
mice (Fig. 2a). The clinical severity of arthritis was simi-
lar in the mice treated with 10  mg/kg of A77 1726 and 
the vehicle-treated mice. However, histological sections 
of the ankle joints stained with H&E and Safranin O 
showed that arthritis was less severe in A77 1726-treated 
mice (at both 10 and 30 mg/kg) compared with the vehi-
cle-treated controls (Fig.  2b). There was a statistically 
significant reduction in the inflammation, bone erosion 
and cartilage damage scores of the mice treated with 10 
or 30  mg/kg A77 1726 compared with those of vehicle-
treated arthritis mice (Fig. 2c).
Anti‑inflammatory effects of A77 1726 are associated 
with reduced expression of inducible nitric oxide synthase 
(iNOS) and nitrotyrosine in mice with inflammatory 
arthritis
We investigated the expression of inflammatory cytokines 
in vehicle (DMSO)- or A77 1726-treated IL-1Ra-KO mic. 
TNF-α, and IL-1β are representative proinflammatory 
cytokines that participate in the inflammatory process in 
the rheumatoid synovium and have systemic effects [22, 
23]. Compared with vehicle-treated IL-1Ra-KO mice, the 
joints from A77 7126-treated IL-1Ra-KO mice (10 and 
30  mg/kg) showed markedly fewer TNF-α- and IL-1β-
expressing cells (Fig. 3a). To determine the degree of oxi-
dative stress in the joints, immunohistochemistry was 
used. The results showed that the expression of nitroty-
rosine and iNOS was reduced in a dose-dependent man-
ner in the joints of A77 1726-treated IL-1Ra-KO mice 
(Fig. 3a). Next, we used ELISA to measure the serum lev-
els of TNF-α, IL-1β, and MDA in the different groups of 
mice. Although not statistically significant, the concen-
trations of TNF-α, IL-1β, and MDA tended to be lower in 
A77 1726-treated arthritis mice than in vehicle (DMSO)-
treated animals (Fig.  3b). These results suggest that 
systemic administration of A77 1726 can inhibit joint 
inflammation, perhaps via inhibiting oxidative stress.
A77 1726 treatment decreased the Th17 population 
and reciprocally increased Foxp3+ Treg cell population 
via regulation of their transcriptional factors
As imbalance between Th17 and Treg cells has been iden-
tified as playing a crucial role in RA pathogenesis [24], 
we investigated whether the populations of Th17 and 
Treg cells were altered in A77 1726-treated IL-1Ra-KO 
mice, IL-17-expressing (mainly Th17) and CD25+ Foxp3+ 
(mainly Treg) CD4+ T cells were analyzed by confocal 
microscopy. The results demonstrated that spleen tis-
sues from arthritis mice treated with A77 1726 showed 
dose-dependent increases in the number of Foxp3+ Treg 
cells and reciprocal decreases in the number of Th17 cells 
compared with spleen tissues from mice treated with 
vehicle (Fig. 4). To investigate the mechanisms mediating 
A77 1726-induced reciprocal regulation of Th17 and Treg 
cell population, the phosphorylated forms of STAT3 and 
STAT5 were analyzed. A77 1726 treatment in arthritis 
mice exhibited attenuated expressions of STAT3 activity 
(both pSTATTyr705 and pSTAT3Ser727) in CD4+ T cells, 
whereas pSTAT5 activity in those cells was significantly 
augmented (Fig. 4). We conclude that A77 1726 treatment 
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Fig. 1 Activation of Nrf‑HO‑1 in Jurkat and murine CD4+ T cells upon exposure to A77 1726. The Nrf2 and HO‑1 activity induced in Jurkat cells (a, b) 
and mouse T cells (c, d) in A77 1726‑treated cells compared with vehicle (DMSO)‑treated cells was determined by immunofluorescence microscopy. 
The cells were cultured for 48 h in the presence or absence of A77 1726 at concentrations ranging from 10 to 100 μM. e Splenic CD4+ T cells from 
C57BL/6 mice were cultured under Th17 cells‑polarizing conditions in the presence or absence of A77 1726. Three days later, the cells were stained 
with antibodies against CD4 and IL‑17 cells. A plot from 1 representative experiment shows the frequencies of IL‑17+ cells among CD4+ T cells 
(left). Mean ± SD values are presented in the form of a histogram. Data are representative of 4 independent experiments with similar results (right). 
***P < 0.001 versus vehicle‑treated cells
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in mice with inflammatory arthritis exerted anti-inflam-
matory effects through regulating Th17 and Treg cells via 
modulating their key transcriptional factors. Interestingly, 
confocal immunostaining in spleens isolated from each 
group of mice demonstrated the significantly increased 
population of HO-1-expressing cells among CD4+ T cells.
Antiarthritis effects of A77 1726 are achieved by selective 
induction of HO‑1 in CD4+ T cells
To identify the mechanisms underlying the anti-inflam-
matory and oxidative stress-reducing properties of A77 
1726 and its potential target cells, we analyzed the mRNA 
expression of ex  vivo splenic CD4+ T cells and splenic 
non-CD4+ T cells isolated from each group of mice. 
mRNA expression of HO-1 was significantly increased 
in splenic CD4+ T cells isolated from A77 1726-treated 
IL-1Ra-KO mice (30  mg/kg) (Fig.  5a). Interestingly, the 
HO-1-inducing property of A77 1726 was seen only in 
CD4+ T cells and not in non-CD4+ splenocytes (Fig. 5a). 
Next, western blot analysis was conducted to confirm the 
HO-1 induction effects of A77 1726. The results showed 
that HO-1 expression in CD4+ T cells of arthritis mice 
was significantly induced by A77 1726 treatment in a 
dose-dependent manner (Fig. 5b). Immunohistochemical 
analysis also showed that A77 1726 increased the number 
of HO-1-expressing splenocytes (Fig. 5c). Taken together, 
these results suggest that the in  vivo anti-inflammatory 
and oxidative stress-reducing effects of A77 1726 were 
related to the HO-1-inducing property and that the ben-
eficial effects were restricted to T cells.
Discussion
The present study showed that the antiarthritis effects 
of A77 1726 in  vivo may be associated with significant 
expansion of Foxp3-expressing Treg cells and recipro-
cal suppression of Th17 cell differentiation. And, anti-
inflammatory effects of A77 1726 shown in arthritis 
mice are associated with inhibited oxidative damage 
Fig. 2 In vivo therapeutic effect of A77 1726 on the development of inflammatory arthritis in mice. a Arthritis score and incidence of arthritis in 
interleukin‑1 receptor antagonist‑knockout (IL‑1Ra‑KO) mice following treatment with A77 1726 or vehicle (DMSO). A77 1726 dissolved in DMSO 
was given intraperitoneally to two different groups (10 or 30 mg/kg; n = 5 mice per group) three times per week for 6 weeks, starting after the first 
A77 1726 treatment. b Representative histological images of joint tissue sections from IL‑1Ra‑KO mice. Tissue sections from the joints of each mouse 
on day 42 after the first A771726 or vehicle treatment were stained with hematoxylin and eosin (H&E; original magnification ×40) and Safranin O 
(original magnification ×200) to examine the severity of arthritis. c Histological scores of inflammation, bone erosion and cartilage damage in mice 
treated with A77 1726 or vehicle (n = 5 mice per group) are shown. Values are the mean ± SD. *P < 0.05; **P < 0.01; ***P < 0.001 versus vehicle‑
treated mice
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and selective HO-1 induction in CD4+ T cells. To our 
knowledge, our study is the first to show an HO-1-induc-
ing activity of leflunomide or its metabolite, A77 1726. 
Our results suggest the potential use of leflunomide in 
treating other inflammatory and degenerative diseases 
by altering the pathogenesis in which impaired HO-1 
activity is implicated. From this viewpoint, it may be val-
uable to understand further the mechanism of action of 
leflunomide, although the drug is already widely used in 
RA patients.
HO is a rate-limiting enzyme in heme catabolism and 
cleaves heme to form biliverdin Ixα, carbon monoxide, 
Fig. 3 Effects of A77 1726 on inflammatory molecules and oxidative stress in the joints of IL‑1Ra‑KO mice. a Tissue sections from the joints of IL‑1Ra‑
KO mice treated with A77 1726 or vehicle were stained with antibodies to TNF‑α, IL‑1β, iNOS, or nitrotyrosine. The cells stained with each antibody 
are shown in brown (left). Expression of proinflammatory molecules and iNOS and nitrotyrosine (oxidative stress markers) was significantly attenu‑
ated in the joints of A77 1726‑treated IL‑1Ra‑KO mice compared with vehicle‑treated animals (right). b Levels of circulating TNF‑α, IL‑1β and MDA in 
the serum of IL‑1Ra‑KO mice in each group. Values are shown as mean ± SD. *P < 0.05; **P < 0.01; ***P < 0.001
(See figure on next page.) 
Fig. 4 A77 1726 reciprocally regulates Th17/Treg imbalance in vivo. Spleen tissues isolated from each group of mice on day 42 after the first A77 
1726 injection were stained for CD4+ IL‑17+ (Th17) cells and CD4+ CD25+ Foxp3+ (Treg) cells using monoclonal antibodies against CD4 (red) and 
IL‑17 (green) or against CD4 (red) CD25 (blue), and FoxP3 (green). To determine the effects of A77 1726 on the phosphorylation of STAT3 and STAT5 
in vivo, isolated spleen tissues was subjected to immunofluorescence staining with monoclonal antibodies against CD4 (red), pSTAT3Tyr705 (green), 
pSTAT3Ser727 (green), or pSTAT5Tyr694 (green). To identify HO‑1‑expressing CD4+ T cells, spleen tissue of IL‑1Ra‑KO mice with or without A77 1726 
treatment was stained with antibodies against CD4 (green) and HO‑1 (red). Original magnification ×400 (left). CD4+ T cells positive for IL‑17, CD25+ 
Foxp3+, pSTAT3Tyr705, pSTAT3Ser727, pSTAT5Tyr694, and HO‑1 were enumerated visually at higher magnification, as projected on a screen (with each 
confocal image representative of 4 fields of view), with results quantified as the mean ± SD number of positive cells in 5 mice per group (right). 
*P < 0.05; **P < 0.01
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and iron [25]. There are two functional isoenzymes of 
HO, HO-1 and HO-2 [26]. HO-1 represents a stress-
responsive protein that is induced by exogenous and 
endogenous factors such as oxidative stress and inflam-
matory mediators [27]. By contrast, HO-2 is consti-
tutively expressed and the expression level of HO-2 
mRNA is maintained within a narrow range in human 
cells [28]. HO-1 deficiency in mice is characterized by 
hepatosplenomegaly, lymphadenopathy, and fibrosis [29]. 
The genetic absence of HO-1 results in abnormal T cell 
function and a subsequent proinflammatory condition 
[29]. Kobayashi et  al. [30] demonstrated that synovial 
tissue from RA patients showed greater expression of 
HO-1 compared with tissue from people with osteoar-
thritis or noninflammatory joint diseases. In our study, 
HO-1 expression was lower in the joint tissues from A77 
1726-treated mice compared with control arthritis mice 
(data not shown). Kobayashi et  al. [30] asserted that 
HO-1 expression may be increased to maintain homeo-
stasis in the inflammatory state of the rheumatoid joint. 
They found that specific inhibition of HO-1 activity in 
RA-derived synovial cells resulted in marked increase in 
inflammatory responses such as TNF-α, IL-6, and IL-8, 
which suggests that endogenously expressed HO-1 plays 
a regulatory role in the development of synovial inflam-
mation. Kobayashi et  al. suggested that modulation of 
HO-1 expression may be a novel treatment strategy in 
human RA.
Leflunomide is classically considered to exert anti-
inflammatory and antiarthritis effects through the inhi-
bition of de novo pyrimidine synthesis and therefore to 
have an antiproliferative effect. The concentrations of 
A77 1726 used in our in vitro study did not alter the pro-
liferation of Jurkat and mouse primary T cells, but A77 
1726 at a concentration of 200 μM exerted antiprolifera-
tive effects in the cells (data not shown). These results 
indicate that lower doses of A77 1726 (up to 100  μM) 
increase the HO-1 activity while maintaining T cell pro-
liferation, which implies newly identified mechanism of 
action for leflunomide.
Given the physiological role of HO-1 in protecting 
against inflammation, some previous studies have sug-
gested a potential role of HO-1 in human RA. Kirino 
et al. [31] demonstrated that TNF-α, the pivotal cytokine 
that has a pathophysiological role in RA pathogenesis, 
suppresses HO-1 expression in RA peripheral blood 
Fig. 5 Selectively increased expression of HO‑1 in splenic CD4+ T cells. a mRNA expression of HO‑1 in splenic CD4+ T cells and non‑CD4+ spleno‑
cytes in each group of mice (n = 5/each group). Values are shown mean ± SD. *P < 0.05. b Mouse splenic CD4+ T cells and non‑CD4+ splenocytes 
were isolated from each group of mice. Lysates were prepared and analyzed by western blotting to detect HO‑1. HO‑1 expression was higher in 
a dose‑dependent manner in splenic CD4+ T cells from A77 1726‑treated mice compared with cells from vehicle‑treated mice. c Representative 
images of HO‑1‑positive cells (stained in brown; original magnification ×400) are shown (left). The results are quantified as the mean ± SD for the 
number of HO‑1‑positive cells (n = 3 mice per group (right). *P < 0.05; **P < 0.01; ***P < 0.001
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mononuclear cells. One case–control study including 
736 RA patients and 846 healthy controls identified that 
HO-1 promotor polymorphism is associated with RA 
susceptibility, which implies that impaired HO-1 activity 
can induce the development of human RA [32]. An HO-
1-inducing strategy may be beneficial in RA patients and 
in people who are susceptible to the disease.
Conclusion
In conclusion, systemic administration of A77 1726, the 
active metabolite of leflunomide, reduced clinical arthri-
tis severity and histological inflammation in this mouse 
model of RA. A77 1726 treatment significantly inhibited 
oxidative damage and reduced proinflammatory cytokine 
expression in inflamed joints. The antiarthritis effect of 
A77 1726 may be associated with significant induction of 
HO-1 activity in CD4+ T cells and reciprocal regulation 
of Th17− Treg cells balance. These data suggest that an 
HO-1-inducing strategy may be a new therapeutic target 
in RA patients.
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